Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

Table 1 Baseline demographics and disease characteristics

Variable	Overall (N = 8)
Median (min, max) age at first infusion, years	37.7 (22.1, 45.2)
Age at time of first infusion (years) category
18 to <30 years	2 (25.0)
30 to <40 years	3 (37.5)
40 to <50 years	3 (37.5)
Race
Asian	1 (12.5)
White	7 (87.5)
ADAMTS13 activity >5%	8 (100)
Extrarenal signs or symptoms of aHUS prior to first infusion of drug	6 (75)
Baseline laboratory values, median (min, max) ^a
Platelet count, ×10⁹/L	119 (36, 473)
LDH, U/L	576 (280, 876)
Serum creatinine, μmol/L	408 (51, 758)
HGB, g/L	72.8 (63, 105.5)
eGFR, mL/min/1.73 m^2(b)	10.0 (10, 18)
Median (min, max) time from delivery to first dose, days	11 (5, 19)
ICU care required	7 (87.5)
Median (min, max) stay in ICU, days	9 (2, 21)
Received PE/PI related to this TMA prior to first infusion of drug	6 (75)
On dialysis within 5 days of first dose	5 (62.5)
Median (min, max) time on dialysis prior to first dose, days	5 (4, 8)
Patients with ≥1 identified pathogenic variant or autoantibody	2 (25)
CFB pathogenic variant	1 (12.5)
Anti-CFH antibodies	1 (12.5)
None identified	5 (65.5)
Data not available	1 (12.5)

^aBaseline values may be after PE/PI in some patients. ^beGFR in patients on dialysis was set to 10 mL/min/1.73 m², and eGFR was calculated using the Modification of Diet in Renal Disease formula. Data displayed as n (%) unless otherwise stated
ADAMTS13 a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13, aHUS atypical hemolytic uremic syndrome, CFB complement factor B, CFH complement factor H, eGFR estimated glomerular filtration rate, HGB hemoglobin, ICU intensive care unit, LDH lactate dehydrogenase, PE plasma exchange, PI plasma infusion, TMA thrombotic microangiopathy

ISSN: 1471-2369